Dynavax Technologies Corp (DVAX)
11.61
+0.26
(+2.29%)
USD |
NASDAQ |
Apr 19, 13:48
Dynavax Technologies Cash from Financing (Quarterly): 1.776M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.776M |
| September 30, 2023 | 2.994M |
| June 30, 2023 | -0.294M |
| March 31, 2023 | -3.09M |
| December 31, 2022 | 0.153M |
| September 30, 2022 | 8.057M |
| June 30, 2022 | 1.028M |
| March 31, 2022 | 10.29M |
| December 31, 2021 | 14.82M |
| September 30, 2021 | 5.322M |
| June 30, 2021 | 3.335M |
| March 31, 2021 | 32.30M |
| December 31, 2020 | 0.066M |
| September 30, 2020 | 1.412M |
| June 30, 2020 | 93.48M |
| March 31, 2020 | 14.54M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 65.74M |
| June 30, 2019 | 0.345M |
| March 31, 2019 | 88.26M |
| December 31, 2018 | 0.006M |
| September 30, 2018 | 0.359M |
| June 30, 2018 | -0.123M |
| March 31, 2018 | 98.83M |
| December 31, 2017 | 18.08M |
| Date | Value |
|---|---|
| September 30, 2017 | 81.71M |
| June 30, 2017 | 58.66M |
| March 31, 2017 | 29.39M |
| December 31, 2016 | -0.216M |
| September 30, 2016 | 0.387M |
| June 30, 2016 | 0.024M |
| March 31, 2016 | 0.336M |
| December 31, 2015 | 0.30M |
| September 30, 2015 | 153.01M |
| June 30, 2015 | 20.51M |
| March 31, 2015 | 0.139M |
| December 31, 2014 | 9.758M |
| September 30, 2014 | 0.06M |
| June 30, 2014 | 0.014M |
| March 31, 2014 | 0.069M |
| December 31, 2013 | 125.29M |
| September 30, 2013 | 0.076M |
| June 30, 2013 | 0.02M |
| March 31, 2013 | 0.015M |
| December 31, 2012 | -14.18M |
| September 30, 2012 | 0.93M |
| June 30, 2012 | 70.04M |
| March 31, 2012 | 2.253M |
| December 31, 2011 | 67.05M |
| September 30, 2011 | 4.787M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-3.09M
Minimum
Mar 2023
93.48M
Maximum
Jun 2020
13.28M
Average
2.994M
Median
Sep 2023
Cash from Financing (Quarterly) Benchmarks
| Supernus Pharmaceuticals Inc | 1.092M |
| Ligand Pharmaceuticals Inc | 5.315M |
| Pacira BioSciences Inc | -1.779M |
| Esperion Therapeutics Inc | 4.471M |
| PetIQ Inc | -2.367M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 13.77M |
| Cash from Investing (Quarterly) | -20.24M |
| Free Cash Flow | 96.46M |
| Free Cash Flow Per Share (Quarterly) | 0.0931 |
| Free Cash Flow to Equity (Quarterly) | 11.76M |
| Free Cash Flow to Firm (Quarterly) | 12.04M |
| Free Cash Flow Yield | 5.90% |